Tonix Pharmaceuticals (TNXP) Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Is TNXP or ABCL more profitable?

AbCellera Biologics has a net margin of -737.56% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. AbCellera Biologics' return on equity of -15.98% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-1,313.87%	-120.96%	-101.28%
AbCellera Biologics	-737.56%	-15.98%	-12.38%

Does the media favor TNXP or ABCL?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.60 beat Tonix Pharmaceuticals' score of -0.36 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, TNXP or ABCL?

Tonix Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of TNXP or ABCL?

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, TNXP or ABCL?

Tonix Pharmaceuticals has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$10.09M	25.85	-$130.04M	-$1.96 thousand	-0.02
AbCellera Biologics	$28.83M	41.71	-$162.86M	-$0.56	-7.20

Do analysts recommend TNXP or ABCL?

Tonix Pharmaceuticals presently has a consensus target price of $585.00, suggesting a potential upside of 1,550.68%. AbCellera Biologics has a consensus target price of $7.50, suggesting a potential upside of 86.10%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

AbCellera Biologics beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks.